2022
AgRP neurons control structure and function of the medial prefrontal cortex
Stutz B, Waterson MJ, Šestan-Peša M, Dietrich MO, Škarica M, Sestan N, Racz B, Magyar A, Sotonyi P, Liu ZW, Gao XB, Matyas F, Stoiljkovic M, Horvath TL. AgRP neurons control structure and function of the medial prefrontal cortex. Molecular Psychiatry 2022, 27: 3951-3960. PMID: 35906488, PMCID: PMC9891653, DOI: 10.1038/s41380-022-01691-8.Peer-Reviewed Original ResearchMeSH KeywordsAgouti-Related ProteinAnimalsDopaminergic NeuronsHypothalamusMiceNeuropeptide YPrefrontal CortexConceptsMedial prefrontal cortexAgRP neuronsNon-selective dopamine receptor antagonistBrain functionPrefrontal cortexHypothalamic AgRP neuronsMedial thalamic neuronsAdministration of clozapineDopamine receptor antagonistVentral tegmental areaOscillatory network activityHigher-order brain functionsHypothalamic agoutiThalamic neuronsChemogenetic inhibitionDopaminergic neuronsReceptor antagonistTegmental areaNeuronal pathwaysSensorimotor gatingAdult miceModulatory impactAmbulatory behaviorConstitutive impairmentNeurons
2019
Dopamine neuronal protection in the mouse Substantia nigra by GHSR is independent of electric activity
Stutz B, Nasrallah C, Nigro M, Curry D, Liu ZW, Gao XB, Elsworth JD, Mintz L, Horvath TL. Dopamine neuronal protection in the mouse Substantia nigra by GHSR is independent of electric activity. Molecular Metabolism 2019, 24: 120-138. PMID: 30833218, PMCID: PMC6531791, DOI: 10.1016/j.molmet.2019.02.005.Peer-Reviewed Original ResearchMeSH KeywordsAction PotentialsAnimalsDopaminergic NeuronsGhrelinMiceMPTP PoisoningNeuroprotective AgentsPeptide FragmentsReceptors, GhrelinSubstantia NigraConceptsSN DA neuronsDA neuronsSubstantia nigraDA cellsDopamine outputNeuronal protectionNeuronal survivalParkinson's diseaseDA neuron survivalDA neuronal survivalDesigner drugs (DREADD) technologyNeuronal pacemaker activityElectrical activityMouse substantia nigraElectric activityNeuron electrical activityAnimal motor behaviorGhrelin activationGHSR activationTetrahydropyridine (MPTP) treatmentNeuroprotective factorsNeuron survivalDopamine neuronsGhrelin receptorExogenous administration
2018
Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson’s Disease
Curry DW, Stutz B, Andrews ZB, Elsworth JD. Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson’s Disease. Journal Of Parkinson's Disease 2018, 8: 161-181. PMID: 29614701, PMCID: PMC6004921, DOI: 10.3233/jpd-171296.Peer-Reviewed Original ResearchMeSH KeywordsAlpha-SynucleinAMP-Activated Protein KinasesAnimalsAutophagyBrainDopaminergic NeuronsHumansNeuroprotective AgentsParkinson DiseaseSignal TransductionConceptsSerine/threonine kinaseFunction of AMPKParkinson's diseaseCellular energy balanceThreonine kinaseCellular stressorsIntracellular α-synuclein aggregatesProtein kinaseAMPK activationAMPK activityNumerous dietary supplementsPreclinical PD modelsNigrostriatal dopaminergic neuronsBroad neuroprotective effectsCell deathCommon neurodegenerative disorderAMPKΑ-synuclein aggregatesNeuroprotective treatmentNeuroprotective strategiesNeuroprotective effectsNeuronal atrophyPD patientsDopaminergic neuronsKinase